Metaverse Leader ImmersiveTouch Obtains FDA Clearance for New Suite of Medical Diagnostic and Treatment Planning Tools

The all-new 510(k) Permission enables ImmersiveTouch to bring its suite of virtual reality products to more radiologists and surgeons.

CHICAGO, November 30, 2021–(BUSINESS WIRE)–ImmersiveTouch, a leading medical technology company developing the digital surgery metaverse, today announced, in conjunction with RSNA 2021, that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its modular software package that allows users to automatically import, view, and segment medical images to create accurate three-dimensional representations. Giving surgeons the ability to diagnose and treat patients virtually will reduce scheduling hours and increase efficiency, which is crucial for doctors and patients.

Segmented 3D models can be used for medical diagnosis, anatomical measurement, treatment planning, and generation of output files for additive manufacturing. ImmersiveTouch is the first patient-specific automatic segmentation technology for generating virtual reality surgical plans that has been used in more than 900 procedures this year and is currently deployed in nearly 70 leading hospitals.

Dr. Matthew Ranzer, MD of Plastic Surgery at Mount Sinai Hospital, says, “One of the things I like about ImmersiveTouch is that it’s not expensive, but it adds value to our system. The ability to simulate these surgical procedures in great detail, makes our operations more efficient and safer for our patients and provides a real benefit to our hospital and our community.”

The healthcare metaverse is booming. According to a study published by Facts and Factors, the virtual reality in healthcare market size is expected to grow at a CAGR of 34.89% to reach $40.98 billion by 2026, from 2.70 billion dollars in 2020.

“As the healthcare industry really begins to embrace technological advancements, we are able to help reduce surgical planning and operating times, improving surgical efficiency and minimizing workflow disruptions” , said Pat Banerjee, CEO of ImmersiveTouch.

ImmersiveTouch COO Jay Banerjee said, “Adding this additional FDA 510(k) clearance for medical diagnosis and treatment planning to our portfolio only reinforces what ImmersiveTouch can offer to surgeons.

About ImmersiveTouch, Inc.

ImmersiveTouch offers clinicians greater accuracy and consistency of care by using technology to simulate each patient’s unique pathology in 3D through its immersive VR metaverse. The company’s proprietary platform integrates solutions for surgical planning, education and patient engagement. www.immersivetouch.com/

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211130005896/en/

contacts

Lynne Flakus
[email protected]